Novartis Q4 Results
↑
Content
Click below to navigate
through the document
KesimptaⓇ FY sales doubled (USD 2.2bn) and on track for USD 4bn peak
based on compelling product profile
GROWTH
↓
Company overview
Financial review
Conclusions
Appendix
References
Sales evolution
USD m, % cc
US
Ex-US
369
63
Launch momentum continues across all regions
FY USD 2.2bn
+99%
• >85k patients treated, majority naive or first switch¹
●
US (+48% cc in Q4): Demand-driven growth
+73%
•
641
Ex-US (+193% cc in Q4): NBRx leadership in 7/10 major markets²
Compelling product profile
188
•
Clinically meaningful efficacy superiority over teriflunomide³
Kesimpta
• 1 minute a month dosing at home/anywhere4
• ~90% find Kesimpta SensoreadyⓇ pen easy and simple to use (US RWE study) 5,6
453
•
5-year efficacy7, safety and tolerability data 8,9
306
Q4 2022
Q4 2023
See last page for references (footnotes 1-9). NBRX - new to brand prescription.
Report.
-
MS Multiple Sclerosis.
Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
9View entire presentation